ARFXF - ARFXF STOCK NEWS

ProMIS Neurosciences presented at the Alzheimer's Association International Conference (AAIC) on July 31, 2022, showcasing its lead candidate, PMN310, an antibody targeting toxic amyloid-beta oligomers in Alzheimer’s Disease. The study demonstrated PMN310's enhanced selectivity and resilience against non-toxic monomers, suggesting greater therapeutic efficacy. Unlike other antibodies that failed in trials, PMN310 maintained binding to toxic oligomers without interference, potentially reducing risks like brain swelling associated with plaque-targeting antibodies. The presentation will be available online post-conference.

ProMIS Neurosciences announced a poster presentation at the Alzheimer’s Association International Conference (AAIC) from July 31 to August 4, 2022. The presentation will focus on the selectivity of their therapeutic candidate PMN310 compared to other amyloid-beta-directed antibodies. Dr. Johanne Kaplan, Chief Development Officer, will present the study results highlighting PMN310's ability to target toxic oligomers despite competing species. Attendees can find the presentation at the San Diego Convention Center and online. More details are available on the ProMIS website.

ProMIS Neurosciences Inc. has received final approval to list its common shares on Nasdaq, effective July 8, 2022. The shares will continue trading on the Toronto Stock Exchange under the same symbol, PMN. This significant milestone is expected to enhance the company's visibility, liquidity, and shareholder base, according to CEO Eugene Williams. ProMIS focuses on developing antibody therapeutics that target misfolded proteins linked to neurodegenerative diseases, including Alzheimer’s and ALS.

ProMIS Neurosciences (OTCQB: ARFXF) announced a 1-for-60 reverse share split effective June 28, 2022, to meet NASDAQ listing requirements. Following the split, the outstanding shares will decrease from 431,731,592 to approximately 7,195,526. While the TSX trading symbol remains PMN, on OTCQB the symbol will change to ARFXFD for 20 business days. The reverse split aims to raise the share price to meet NASDAQ's minimum requirement of US$4.00. However, the company acknowledges the uncertainty surrounding the approval of its NASDAQ listing application.

ProMIS Neurosciences has amended its articles to issue 70,000,000 Series 1 Preferred Shares to settle outstanding debentures. These shares offer no voting rights but grant a liquidation preference of US$0.10 each. Holders can convert Series 1 Shares into Common Shares at a 1:1 ratio upon certain conditions, including raising at least US$30 million in gross proceeds. The company specializes in developing antibody therapeutics targeting misfolded proteins involved in neurodegenerative diseases, including Alzheimer's and ALS.

ProMIS Neurosciences Inc. (OTCQB: ARFXF) has announced the issuance of 70 million Series 1 Preferred Shares at $0.10 each to settle $7 million in debt with seven creditors. This strategic move allows the company to conserve cash and aims to meet the listing requirements of a major North American stock exchange. The Series 1 Shares are convertible into Common Shares at a 1:1 ratio. The transaction is subject to TSX acceptance. Financial adjustments show total assets of approximately CAD 18.01 million and liabilities decreasing from approximately CAD 13.37 million to CAD 3.75 million post-conversion.

ProMIS Neurosciences Inc. (OTCQB: ARFXF) has filed a Form 10 registration statement with the SEC to list its common shares on Nasdaq. This move is part of the company’s strategy to transform and enhance capital formation. The lead candidate for Alzheimer's, PMN310, is on track for an IND filing by year-end after receiving positive FDA feedback. ProMIS aims to leverage positive data from Eisai's lecanemab study to improve sentiment in the AD field. However, approval for the Nasdaq listing is not guaranteed, and the registration remains subject to SEC review.

ProMIS Neurosciences (OTCQB: ARFXF) participated in the Neuro4D International Conference in Mainz, Germany on May 16-17, 2022. Dr. Neil Cashman, ProMIS CSO, presented on the role of toxic Abeta oligomers in Alzheimer's disease. He emphasized the importance of targeting these oligomers to avoid 'target distraction' from non-toxic monomers, which can hinder effective treatment. The company utilizes a proprietary computational platform to design antibodies selectively targeting misfolded proteins implicated in neurodegenerative diseases, specifically developing PMN310 for Alzheimer's.